Drug intelligence / Profile preview

shCIRH1A lentivirus

Development stage
Preclinical
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
Administration
Intravenous, Intratumoral, Intralesional, Intrathecal, Intravitreal, Intraperitoneal, Intra-arterial, Parenteral
01

Overview

shCIRH1A lentivirus is a research-grade gene therapy tool consisting of a lentiviral vector that delivers short hairpin RNA (shRNA) specific to the CIRH1A (Cirhin) gene. CIRH1A is a ribosomal protein that is often overexpressed in colorectal cancer and is associated with cell proliferation and survival. The lentivirus-mediated delivery of shRNA triggers the RNA interference (RNAi) pathway, leading to the degradation of CIRH1A mRNA and subsequent knockdown of the Cirhin protein. In preclinical models, such as RKO colorectal cancer cell lines, this knockdown has been shown to inhibit cell growth, induce apoptosis, and cause G1 phase cell cycle arrest. It serves as a molecular tool for studying the oncogenic potential of ribosomal proteins and exploring gene silencing as a therapeutic strategy.

Other names
lentivirus-mediated CIRH1A siRNAshRNA-CIRH1A lentivirusshRNA-CIRH-1A lentivirusshRNA-CIRH 1A lentiviruslentivirus-mediated small interfering RNAs targeting CIRH1A
02

Targets

Cirhin mRNA

Beyond the preview

Go deeper on shCIRH1A lentivirus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on shCIRH1A lentivirus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call